Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT COVID-19 Trial
NCT04324463Phase 3Completed
- Sponsor
- Population Health Research Institute
- Start
- Apr 2020
- Primary completion
- Dec 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 12
01
Overview
A Phase 3 trial of colchicine, aspirin, rivaroxaban in coronavirus disease 2019 (COVID-19), sponsored by Population Health Research Institute. Started Apr 2020; status: completed.
02
Drugs
colchicineaspirinrivaroxaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04324463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324463.